Biocryst Pharmaceuticals (BCRX) Operating Income (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Operating Income came in at -$701.6 million in Q1 2026, down 3405.22% YoY from $21.2 million in Q1 2025, and down 369.45% on a QoQ basis from $260.4 million in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Operating Income (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 17 years of Operating Income data on file, last reported at -$701.6 million in Q1 2026.
- Quarterly Operating Income fell 3405.22% year-over-year to -$701.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$381.8 million (down 1251.08% YoY) and the FY2025 annual result came in at $341.0 million, up 13508.93% from the prior year.
- Operating Income retreated to -$701.6 million in Q1 2026, from $260.4 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $260.4 million in Q4 2025 to a low of -$701.6 million in Q1 2026.
- A 5-year average of -$36.2 million and a median of -$14.5 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2025 — Operating Income surged 5876.06% — and 2026, when it tumbled 3405.22%.
- Tracing BCRX's Operating Income over 5 years: stood at -$46.3 million in 2022, then advanced by 7.86% to -$42.7 million in 2023, then jumped by 89.44% to -$4.5 million in 2024, then surged by 5876.06% to $260.4 million in 2025, then plunged by 369.45% to -$701.6 million in 2026.
- The last three Operating Income figures came in at -$701.6 million (Q1 2026), $260.4 million (Q4 2025), and $29.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | -231.00 Mn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 837.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 1.26 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 330.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 6.30 Mn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 151.50 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 248.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.10 Bn | 214.41 Mn | 98.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 98.47 Mn |
| Mar 31, 2026 | -701.60 Mn |
| Dec 31, 2025 | 260.39 Mn |
| Sep 30, 2025 | 29.59 Mn |
| Jun 30, 2025 | 29.79 Mn |
| Mar 31, 2025 | 21.23 Mn |
| Dec 31, 2024 | -4.51 Mn |
| Sep 30, 2024 | 7.69 Mn |
| Jun 30, 2024 | 8.76 Mn |
| Mar 31, 2024 | -14.49 Mn |
| Dec 31, 2023 | -42.67 Mn |
| Sep 30, 2023 | -11.92 Mn |
| Jun 30, 2023 | -20.70 Mn |
| Mar 31, 2023 | -28.42 Mn |
| Dec 31, 2022 | -46.31 Mn |
| Sep 30, 2022 | -17.45 Mn |
| Jun 30, 2022 | -34.72 Mn |
| Mar 31, 2022 | -49.96 Mn |
| Dec 31, 2021 | -52.18 Mn |
| Sep 30, 2021 | -44.58 Mn |